tradingkey.logo

BRIEF-Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

ReutersFeb 6, 2025 1:34 PM

- Biocon Ltd BION.NS:

  • EQUILLIUM ANNOUNCES POSITIVE DATA FROM PHASE 2 STUDY EVALUATING ITOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

  • EQUILLIUM INC - ITOLIZUMAB GENERALLY WELL TOLERATED IN PHASE 2 STUDY

  • EQUILLIUM INC - ITOLIZUMAB ACHIEVES 16.7% ENDOSCOPIC REMISSION IN PHASE 2 STUDY

Source text: ID:nBwbcr7K5a

Further company coverage: BION.NS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI